This methodology allowed the decrease of LRRK2 expression in the nervous system of mice models of PD and the reduction of α-syn aggregation and dopaminergic neuronal damage without modifying LRRK2 expression in other peripheral tissues, such as the kidney and lung, avoiding side effects [202]. Here, LRRK2 is linked to Parkinson disease.